This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. Anthracyclines are a well-established class of cancer drugs that are used to treat several types of cancer.
Video 8 in 8: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC kchalko Thu, 05/23/2024 - 09:56 In this video in the 8 in 8 Series, Dr. Dwight Owen (Ohio State University) discussed advances in biomarker testing and neoadjuvant immunotherapy for resectable non-small cell lung cancer.
Recent research suggested that the weight loss market was estimated to be worth $224 billion annually in 2021 and is estimated to exceed $400 billion by 2024 1. These stages can range from mild fatty liver infiltration to serious scarring and fibrosis terminating in liver cirrhosis and potentially liver cancer. 2024 Jun 21.
9-11, 2024. The event is offered as an interdisciplinary and interspecialty course to provide clinicians and researchers with the tools needed to improve the cardiovascular (CV) health of cancer patients in everyday practice. 9-11, 2024, with program planners preparing a robust program.
tim.hodson Wed, 12/18/2024 - 14:52 Dec. 11, 2024 Genetesis, Inc. The current version of the CardioFlux Score analyzes 14 unique biomarkers that quantify the heart muscle's electrical activity and then compares those results to a benchmark of healthy, symptom-free individuals. has launchedthe CardioFlux Membership program.
I have covered this topic previously here , but it is clear that inflammation plays a major role in the initiation and progression of coronary artery disease, and the inflammatory biomarker hsCRP is tightly connected to this process. Obesity is the second leading cause of preventable cancers after smoking 9. 2024 Jun 21.
milla1cf Tue, 06/11/2024 - 18:41 June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac amyloidosis, a condition referred to as the “Alzheimer’s disease of the heart.” This research was presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.
Video The Surgeon’s Role in Managing Patients with Resectable NSCLC smccarthy Fri, 03/08/2024 - 14:51 In this video, Dr. Leah Backhus, thoracic surgeon and professor of cardiothoracic surgery at Stanford Medicine, discusses the surgeon’s role in managing patients with resectable non-small cell lung cancer. Duration 12 min.
Understanding where you sit on this continuum is a key part of defining your future risk of heart disease but also dementia, and many cancers. The further along the line of insulin resistance you sit, the higher your risk of all the leading causes of death, including heart disease, dementia and many cancers 5. 2024 Jun 21:e033997.
Credit: Feinstein Institutes) milla1cf Wed, 05/08/2024 - 10:57 May 8, 2024 — Ultrasound could one day complement or even replace drugs to treat diseases. Feinstein Institutes’ Dr. Stavros Zanos is the senior author on the new bioelectronic medicine ultrasound paper.
They are dying less often from the two leading causes of death: Cardiovascular Disease and Cancer. To the point that those with 6 to 7 of the healthy factors in place had essentially eliminated the increased risk of dying from cardiovascular disease or cancer compared to those without type 2 diabetes. BMC Med 22 , 114 (2024).
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Such support is provided by a number of government institutions and charities, including the Medical Research Council, National Institute for Health and Care Research, Department of Health and Social Care, British Heart Foundation, Cancer Research UK and Wellcome. I don’t think so. I have read some utter bollocks in my life.
tim.hodson Thu, 11/21/2024 - 13:27 Nov. 21, 2024 — Royal Philips plans to unveil its next-generation 1.5T BlueSeal MR wide-bore scanner at RSNA 2024 in Chicago, Dec. will be demonstrated in the Philips booth (#6730) at RSNA 2024. 70cm MRI system available today [4]. The next generation Philips BlueSeal 1.5T
If you have reduced your risk of heart disease and cancer as you age, other threats rise to the surface. 2 Powerpenia Should be Considered a Biomarker of Healthy Aging. Sports Med - Open 10 , 27 (2024). 2024 Mar 6;5:1302574. 12 Powerpenia Should be Considered a Biomarker of Healthy Aging. Fall Prevention.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content